China Pharma Holdings (CPHI) Free Cash Flow Growth (3y) (2013 - 2026)
China Pharma Holdings (CPHI) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 14.41% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 216.31% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 4.08% |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 49.44% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -10.40% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -9.38% |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 134.18% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | China Pharma Holdings | 41.94 Mn | 41.64 Mn | 83,566.00 | 46.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.04% |
| Dec 31, 2025 | -37.20% |
| Sep 30, 2025 | -92.27% |
| Jun 30, 2025 | 37.56% |
| Mar 31, 2025 | 46.88% |
| Dec 31, 2024 | 49.79% |
| Sep 30, 2024 | 64.82% |
| Jun 30, 2024 | -28.21% |
| Mar 31, 2024 | -28.32% |
| Dec 31, 2023 | -26.98% |
| Sep 30, 2023 | 57.98% |
| Jun 30, 2023 | 19.17% |
| Mar 31, 2023 | -33.62% |
| Dec 31, 2022 | 118.66% |
| Sep 30, 2022 | -27.47% |
| Jun 30, 2022 | -49.12% |
| Mar 31, 2022 | -41.59% |
| Dec 31, 2021 | -30.83% |
| Sep 30, 2021 | -43.99% |
| Jun 30, 2021 | 53.09% |